XML 30 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statement of Equity - USD ($)
$ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Other Paid-In Capital
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Loss
Cumulative Effect, Period of Adoption, Adjustment
Treasury Stock
Non- controlling Interests
Beginning Balance at Dec. 31, 2017 $ 34,569 $ 48 $ 1,788 $ 39,902 $ 41,350 $ 322 $ (4,910) $ (274) $ (43,794) $ 233
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net Income Attributable to Merck & Co., Inc. 6,220       6,220          
Other comprehensive income (loss), net of taxes (361)           (361)      
Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018) (5,313)       (5,313)          
Treasury stock shares purchased (9,091)     (1,000)         (8,091)  
Net income (loss) attributable to noncontrolling interests (27)                 (27)
Distributions attributable to noncontrolling interests (25)                 (25)
Share-based compensation plans and other 862     (94)         956  
Ending Balance at Dec. 31, 2018 26,882   1,788 38,808 42,579   (5,545)   (50,929) 181
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net Income Attributable to Merck & Co., Inc. 9,843       9,843          
Other comprehensive income (loss), net of taxes (648)           (648)      
Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018) (5,820)       (5,820)          
Treasury stock shares purchased (4,780)     (1,000)         (5,780)  
Net income (loss) attributable to noncontrolling interests (66)                 (66)
Distributions attributable to noncontrolling interests (21)                 (21)
Share-based compensation plans and other 611     (148)         759  
Ending Balance at Dec. 31, 2019 26,001   1,788 39,660 46,602   (6,193)   (55,950) 94
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net Income Attributable to Merck & Co., Inc. 7,067       7,067          
Other comprehensive income (loss), net of taxes (441)           (441)      
Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018) (6,307)       (6,307)          
Treasury stock shares purchased (1,281)               (1,281)  
Net income (loss) attributable to noncontrolling interests 15                 15
Distributions attributable to noncontrolling interests (22)                 (22)
Share-based compensation plans and other 372     (72)         444  
Ending Balance at Dec. 31, 2020 $ 25,404   $ 1,788 $ 39,588 $ 47,362   $ (6,634)   $ (56,787) $ 87